International Society For Apheresis

Linked in

Thu, 5 Feb 2026 10:23:54 +0900

Save the Date / ISFA 2027 San Diego

Fri, 9 Jan 2026 11:38:06 +0900

We are excited to announce the date and Venue of ISFA 2027 Congress have just decided.

Please save the date!

ISFA 2027 Congress
Setting Higher Standards in Apheresis Medicine: Innovative Therapies and Technologies

August 5-7, 2027

ISFA SMS Committee

Fri, 9 Jan 2026 11:29:05 +0900

ISFA SMS Committee　Members

America

Amber Sanchez (USA)
Christina Anderson（USA)
Christopher Patriquin（CAN）
Dobri Kiprov (USA)
Flora Siami (USA)
Jill Adamski（USA）
Katherine Twombley (USA)
Laura Collins（USA）
Maya Safarova (USA)
Patrick Moriarty (USA)
Rasheed Balogun（USA）
Tibor Fulop (USA)

Europe

Bernd Hohenstein（DEU)
Chimezie Okwuonu（NGA)
Kurt Derfler (AUT)
Lionel Rostaing (FRA)
Luigi Vermaglione（ITA)
Olivier Moranne（FRA）
Wladimir Szpirt (DEK)

Pan-Pacific

Kriengsak Vareesangthip (THA)
Kuo-Juei Lin (ROC)
Kyou-Sup Han (KOR)
Hidenori Matsuo (JPN)
Makio Kusaoi（JPN)
Michio Mineshima（JPN）
Mariko　Harada-Shiba　（JPN）
Satoru Oji（JPN）
Tadao Akizawa (JPN)

Lists of organizations

ISFA SMS Policy

Thu, 6 Nov 2025 09:51:14 +0900

International Society for Apheresis (ISFA)

Social Media Policy

Purpose

This policy safeguards patient privacy, scientific integrity, the reputation of the organization, and legal compliance in all ISFA’s social media (ISFA SMS) activities.

Rules & Guidelines

1. Patient privacy (PII) — Strictly prohibited
a. Posting any personally identifiable information (PII) of patients is strictly prohibited. PII includes direct identifiers (e.g., name, face, voice) and indirect/unique identifiers that could reasonably lead to identification (e.g., tattoos, rare conditions, distinctive backgrounds, dates, locations, device IDs, and similar data).

b. Liking & Sharing Content
It must be ensured that the content is publicly visible or approved for sharing.
Content containing personally identifiable information (PII) of patients must not be shared without consent. Be aware that likes and shares from official accounts may be interpreted as organizational endorsement. Always follow the platform’s privacy rules and guidelines.
Approval must be obtained from the Account Owner or Compliance Reviewer if there is any doubt about the appropriateness of sharing.

2. Images and consent
If any individual (including non-patients) is identifiable in posted images/audio/video, written informed consent must be obtained before posting. If consent cannot be obtained, the images must be edited or withheld to ensure that the individual cannot be identified (e.g., by cropping, blurring). For minors, consent must be obtained from a parent or legal guardian. The headquarters shall retain consent records for at least 5 years.

3. Political and Religious content
Posts related to political or religious advocacy are generally prohibited. Posts that highlight widely celebrated cultural events—such as Lunar New Year (Spring Festival), Ramadan, Easter, Diwali, Halloween, Christmas, or traditional observances (e.g., New Year’s shrine visits in Japan or Bon Odori)—are permitted only when presented neutrally as cultural exchange (without proselytizing and advocacy).

4. Scientific Accuracy and Citation
Academic or scientific content may be posted only if based on publicly available publications or guidelines. Proper citation, including DOI or official URL, must be provided. Preprints must be clearly labeled as not peer reviewed.

5. Non-Guideline Practices
Posts promoting treatment methods or procedures that are not aligned with established clinical guidelines are strictly prohibited on official accounts. Educational descriptions of such topics are allowed only under Rule 17 (Off label/Investigational), provided they are clearly labeled and presented in a neutral tone.

6. Personal Accounts Disclosing Affiliation
When posting from a personal account while stating ISFA affiliation, a disclaimer must be included clarifying the views are those of the individual, not ISFA (see Appendix A for templates). This is required whenever affiliation is stated.

7. Commercial Promotion
Commercial promotion or advertising (e.g., endorsement of products, services, or specific companies) is prohibited on official accounts. Caution must be exercised when posting from personal accounts as well; any relevant conflicts must be disclosed.

8. Professional Tone
Language that could be perceived as offensive, derogatory, or disrespectful toward individuals or groups must not be used. All posts should maintain a professional and respectful tone even for humorous or satirical content.

9. No Individualized Clinical Direction
Posts must not encourage specific clinical decisions based solely on social media content (e.g., “this treatment works”). No individualized diagnosis or treatment advice should be given on social channels (see Rule 15).

10. Pre-Posting Checks
Before posting, all content must be verified to ensure it is free of misinformation, copyright violations, or confidential material. For official accounts, a two-person review rule (content writer + reviewer) must be applied. When in doubt, consultation with a supervisor, a compliance officer, or public relations representative is required.

11. Takedown/Modification Rights
The Secretariat or designated social media managers may remove or modify posts deemed inappropriate or non-compliant without prior notice, to protect the organizational integrity. When feasible, a brief notification will be sent to the author after the action, and a record of the action will be kept.

12. Scope & Roles
This policy applies to all official ISFA social media accounts and to personal accounts where an ISFA affiliation is stated. The Secretariat designates:
• Account Owners： ISFA Headquarters - access control & publishing
• Content Editors： drafting & fact checking
• Compliance Reviewers：final check and approval for policy/legal/privacy

• Responsibility： ISFA SMS Committee - approval of the general editorial direction and final decision in case of doubt or conflict.

A simple posting workflow is provided in Appendix B.

13. Data Protection & International Compliance
ISFA will comply with applicable data protection laws in every jurisdiction where it processes personal data, including but not limited to: GDPR (EU), HIPAA (U.S.; when ISFA acts as or partners with a covered entity or business associate handling PHI), APPI (Japan), and LGPD (Brazil). Where multiple regimes may apply, ISFA will apply the stricter standard where feasible.

The Secretariat maintains a register of lawful bases, consent records, cross border data considerations, and takedown requests, and executes removals via the Rule 11 process upon valid legal or privacy requests. See Appendix C for named references and official sources.

14. Informed Consent Standards
Use organization-approved consent forms that specify platforms, territories, and duration. For event photography, obtain group or speaker consent according to the venue policy; clearly display “Photo Policy” signage where applicable.

15. No Personal Medical Advice & Handling Health Inquiries
Do not provide personalized medical advice, diagnosis, or treatment recommendations. Use standardized language to direct individuals to their own healthcare providers (see Appendix A). Escalate critical safety messages (e.g., self-harm) per crisis protocol (Rule 24).

16. Embargoes & Conflicts of Interest (COI)
Respect journal and conference embargoes and confidentiality. Disclose COI when posting about studies, products, sponsors, or your own research/relationships.

17. Off-Label / Investigational Content
Educational discussion of investigational or off-label use must be clearly labeled; include citations; avoid prescriptive statements and avoid portraying efficacy/safety as established. Refer readers to current guidelines and product labeling.

18. Event Coverage: Photos, Quotes, Slides
Follow venue and speaker policies. Do not post slides or recordings marked “no photo/recording.” Obtain speaker consent for direct quotes, attribute accurately.

19. AI Generated Content
AI-generated text or images must be human-reviewed for accuracy and bias and labeled appropriately (e.g., “AI generated; not a real patient”). Do not fabricate data, quotes, or realistic images of patients.

20. Accessibility
Provide alternative text for images, add captions/subtitles for videos when feasible, and supply transcripts for text-heavy graphics to ensure accessibility.

21. Account Security
Use official emails, strong passwords, and multi-factor authentication. Limit admin roles, review access quarterly, and use only approved third-party tools and link shorteners.

22. Language and Translation Quality
Maintain a professional tone across languages. Ensure meaning-equivalent translations. Avoid unreviewed machine translation. Maintain an official glossary for key terms. Regional Representatives may translate postings when doing so helps to promote apheresis within their own regions.

23. Community Management & Moderation
Moderate comments to remove spam, harassment, discriminatory content, misinformation, and personal health requests. Document takedowns with timestamp, URL, and rationale.

24. Crisis & Incident Response
In legal, reputational, or safety incidents: pause scheduled posts; escalate to the Secretariat and President; consider a holding statement; maintain an incident log and post-mortem.

25. Records & Retention
Archive official posts, edits, approvals, and consent/takedown logs for 5 years per the organizational records policy.

26. Metrics & Review Cadence
Quarterly review of performance (reach, engagement), compliance incidents, and audience feedback. The results shall be reported to the Board. Update this policy as needed.

27. Enforcement
Possible actions include content removal, access suspension, mandatory training, and referral to governance bodies. Provide an internal channel for reporting concerns.

Appendix A (Disclaimers Templates) -Standard and Simplified

No medical advice: “Information shared here is for general education only and is not a substitute for professional medical advice. If you have health questions, please consult your healthcare provider.”
Views my own: “The views expressed are my own and do not necessarily reflect those of ISFA.”
Off-label/Investigational: “This post discusses investigational/off label use for educational purposes and is not an endorsement. Please refer to current clinical guidelines and product labeling.”
AI generated image: “Image generated with AI; not depicting real persons or patients.”
Simplified version: General info only, not medical advice. Views are my own. Educational discussion only. AI images not real people

Appendix B — Posting Workflow (Official Accounts)

Draft (Content Writer) → Fact check & Citation check → Compliance Review (Reviewer) →Posting (Account Owner) → Publish (Account Owner)

Emergency: Post freeze → Escalate to Secretariat/President → Prepare holding statement → log the incident.

Appendix C — Named legal references (non exhaustive)

Purpose of this appendix: This appendix lists the primary data protection laws referenced in Rule 13 and elsewhere in the policy, and should be consulted for authoritative definitions and scope.

• GDPR — EU General Data Protection Regulation.

HIPAA — U.S. Health Insurance Portability and Accountability Act (Privacy & security Rules; PHI).

• APPI — Japan’s Act on the Protection of Personal Information.

• LGPD — Brazil’s Lei Geral de Proteção de Dados Pessoais.

(Consult official sources for current versions.)

ISFA 2025 Banglkok

Mon, 27 Oct 2025 15:57:06 +0900

ISFA2025_Program_final

ISFA 2025

Mon, 28 Jul 2025 16:46:54 +0900

We are excited to announce the successful conclusion of the ISFA 2025 Congress in Bangkok.
The congress brought together colleagues and friends from around the world, and it was a truly inspiring and memorable experience for everyone involved.
From the high-quality scientific sessions to the warm hospitality and vibrant atmosphere, every moment was filled with learning, connection, and enthusiasm.
We sincerely thank all attendees, speakers, and partners who made this event such a remarkable success.

ORGANIZATION 14TH TERM (2025－2027)

Thu, 24 Jul 2025 09:11:37 +0900

Current Presidential greeting

14th Term President
Raheed A. Balogun

Prof. Dr. med.

Division of Nephrology

University of Virginia

Distinguished colleagues, friends, and members of the global apheresis community,

It is an extraordinary honor to serve as the role of President of the International Society for Apheresis. I am humbled by the trust you have placed in me, and deeply grateful to Ken Yamaji my predecessor, Andre Kaplan, my long-term mentor, all past presidents and members of the council and members at large of ISFA who have built this society into the global beacon it is today. The support of my wife and family cannot be overemphasized.

ISFA thrives because of the dedication of its international members, from Europe and Asia to the Americas, Africa and Oceania. Together, we represent not just different regions, but also different specialties: nephrology, hematology, neurology, transplantation, and critical care. Our shared commitment to advancing therapeutic apheresis binds us.

Strategic Vision Overview – 'Advancing ISFA: 2025–2027'

Over the next two years, I ask that we consider focusing on four strategic priorities:

1. Global Equity in Apheresis Access

2. Education, Training, and Competency Support

3. Interdisciplinary Research and Innovation

4. Organizational Strength and Visibility

Global Equity in Apheresis Access

Many parts of the world still lack access to life-saving apheresis therapies. My vision is to deepen ISFA's collaboration with national societies to promote:

- Regional mentorship programs

- Low-cost equipment partnerships

- Support for emerging apheresis centers in LMICs

- Joint sessions at regional meetings in Africa, Southeast Asia, and South America

Education, Training, and Competency Support

We will expand the ISFA Learning Platform, integrating:

- Updated access to relevant clinical guidelines

- Monthly virtual grand rounds and case discussions

- A global apheresis fellowship directory

- A 'Visiting Scholar' exchange initiative for young practitioners and nurses

Interdisciplinary Research and Innovation

ISFA must become a driver, not just a recorder, of apheresis innovation. We will consider:

- Launch an ISFA Collaborative Registry Project

- Support multicenter trials for non-traditional indications

- Expand publication opportunities in our affiliated journal

Organizational Strength and Visibility

We plan to invest in:

- A modernized ISFA website

- Professional Congress Organization (PCO) partnerships

- Enhanced social media

- Look to strengthen alliances with ASFA, WAA, ISN, EBMT, and others

Allow me to briefly reflect on my own personal journey; from birth in Toronto, Canada to parents who were international students to my formative years and medical school in Ibadan, Nigeria followed by specialist training in Connecticut, USA and now a career that has brought me to full tenured professorship at University of Virginia, USA while practicing Apheresis Medicine. I am a multinational citizen of the world that has benefited from the power of mentorship, access, and service to others that have all shaped my path. I am committed to paying that forward during my term as ISFA President and beyond.

It gives me great pleasure to announce the 16th ISFA World Congress in 2027, which will be held in the United States.

After extensive evaluation, we are pleased to announce that the final decision will be made in the following month or two and presented to the council for ratification. Regardless of final choice, it will be an exceptional event.

In closing, I invite every member to engage actively. Join a committee. Mentor a colleague. Submit a case or abstract.

Together, we will advance the science, clinical practice, and global reach of apheresis.

Thank you, and I look forward to serving you.

The Officers and The Board of Trustees of 14th Term　(2025-2027)

President

Rasheed A. Balogun (USA)

President-elect

Lionel Rostaing (FRA)

Immediate Past-President

Ken Yamaji (JPN)

Congress President

(16th America)

Rasheed A. Balogun (USA)

Vice President

Amber Sanchez (USA)

Jan Kielstein (DEU)

Takafumi Ito (JPN)

Secretary Treasurer

Makio　Kusaoi（JPN）

Editor-in Chief

Takafumi　Ito (JPN)

Regional Officers

America

Antonio Torloni (USA)

Christopher Patriquin　（CAN）

Maya Safarova（USA)

Patrick Moriarty (USA）

Europe

Bernd Hohenstein（DEU）

Wladimir Szpirt（DEK）

Wolfgang Ramlow（DEU）

Pan-Pacific

Hidenori Matsuo（JPN）

Kriengsak Vareesangthip（THA）

Kou-Juei Lin（TWN）

Takuya Ueno (JPN)

The Board of Trustees

America

Christina Anderson（USA)
Christopher Patriquin（CAN）
Dobri Kiprov (USA)
Flora Siami (USA)
Jeffrey Winters (USA)
Jill Adamski（USA）
Katherine Twombley (USA)
Laura Collins（USA）
Patrick Moriarty (USA)
Tibor Fulop (USA)

Europe

Bernd Hohenstein（DEU)
Chimezie Okwuonu（NGA)
Kurt Derfler (AUT)
Luigi Vermaglione（ITA)
Olivier Moranne（FRA）
Reinhard Klingel (DEU)
Wladimir Szpirt (DEK)
Wolfgang Ramlow (DEU)

Pan-Pacific

Kyou-Sup Han (KOR)
Lanjuan Li (CHN）
Makio Kusaoi（JPN)
Masaaki Fukunishi（JAN）
Michio Mineshima（JPN）
Mariko　Harada-Shiba　（JPN）
Yoko Yokoyama（JPN)
Satoru Oji（JPN）
Shigeo Ogawa（JPN）
Tadao Akizawa (JPN)

Lists of organizations

New Corporate Member / Terumo BCT

Fri, 8 Nov 2024 09:09:46 +0900

New Corporate Member / Terumo Blood and Cell Technologies

We are pleased to announce that a new corporate membr has joined ISFA.

We look forward to making meaningful progress together, achieving fruitful outcomes, and contributing to the development of our field.

We are grateful to have 9 companies who resonate with our goals and ideals and are committed to supporting our efforts as we work together toward a brighter future.

You can see our corporate members here.

Terumo Blood and Cell Technologies

Thu, 31 Oct 2024 17:17:50 +0900

Headquartered in Lakewood, Colorado, Terumo Blood and Cell Technologies is a global leader in blood component, therapeutic apheresis, and cellular therapy technologies, serving customers in more than 150 countries. We believe in the potential of blood and cells to do even more for patients than they do today. This belief unites our organization, inspires our innovation, and strengthens our collaboration with customers.

We are proud to offer an industry-leading therapeutic apheresis platform, multiple therapeutic protocols, and data, consulting, support; automated platforms and services to support cell therapy developers and researchers; plasma collection technology, services, and software; automated blood collection and processing innovations; and pathogen reduction technology.

Originally established in 1964 as COBE Laboratories, today, nearly 7,000 associates around the world are deeply committed to mission to Contribute to Society through Healthcare. One way we back these words is through our pledge to be a conscientious corporate citizen and conduct our business in a way that provides social, environmental, and economic benefit.

At Terumo Blood and Cell Technologies, discovery never stops. We share a passion for thinking in new and different ways and we are proud to support education and research through a variety of community involvement activities as well as by providing opportunities to advance treatment options for patients. We know the work we do matters and has the potential to fundamentally improve health care. We remain dedicated to ensuring the lifesaving gift of blood is available around the world and to meeting and exceeding the needs of our customers and the patients we ultimately serve.

http://www.terumobct.com

Impact Factor for 2024 is 1.2

Tue, 25 Jun 2024 09:07:02 +0900

We are pleased to share that the Therapeutic Apheresis and Dialysis has received a 2024 Impact Factor of 1.2.

Privacy Policy

Mon, 15 Apr 2024 10:12:33 +0900

ISFA HP Privacy policy - GDPR

Past Conferences

Fri, 8 Sep 2023 15:54:50 +0900

Past Congresses

Impact Factor for 2022 is 1.900

Fri, 30 Jun 2023 15:10:53 +0900

We are pleased to share that the Therapeutic Apheresis and Dialysis has received a 2022 Impact Factor of 1.900.

ORGANIZATION 13TH TERM (2023－2025)

Mon, 12 Jun 2023 15:44:16 +0900

Current president greeting

13th Term President
Ken Yamaji

Prof. Dr. med.

Dear Colleagues,

President of ISFA

The Officers and The Board of Trustees of 13th Term　(2023-2025)

President

Ken Yamaji (Japan)

President-elect

Rasheed Balogun (USA)

Immediate Past-President

Bernd Hohenstein (Germany)

Congress President

(15th Pan-Pacific)

Kriengsak Vareesangthip (Thailand)

Vice President

Amber Sanchez (USA)

Lionel Rostaing (France)

Mariko Harada-Shiba (Japan)

Secretary Treasurer

Yoshihiro Endo (Japan)

Ken Yamaji（Japan）Oct 2023 ～

Editor-in Chief

Tadao Akizawa (Japan)

Regional Officers

America

Paul Malchesky, Patrick Moriarty, Antonio Torloni

Europe

Wladimir Szpirt, Volker Witt, Wolfgang Ramlow

Pan-Pacific

Hidenori Matsuo, Kou-Juei Lin, Tadao Akizawa

The Board of Trustees

America

Patrick Moriarty (USA)
Jay Raval (USA)
Flora Siami (USA)
Antonio Torloni (USA)
Takuya Ueno (USA)
Tibor Fulop (USA)
Dobri Kiprov (USA)
Anne Winkler (USA)
Katherine Twombley (USA)
Jeffrey Winters (USA)

Europe

Wladimir Szpirt (Denmark)
Wolfgang Ramlow (Germany)
Volker Witt (Austria)
Jan Kielstein (Germany)
Volker Schettler (Germany)
Kurt Derfler (Austria)
Alexey Sokolov (Russia)
Andreas Kronbichler (Austria)
Reinhard Klingel (Germany)

Pan-Pacific

Kyou-Sup Han (Korea)
Nobuhiko Koga (Japan)
Michio Mineshima (Japan)
Norio Hanafusa（Japan)
Shigeo Ogawa (Japan)
Takuji Asano (Japan)
Lanjuan Li (China)
Takafumi Ito (Japan)
Makio Kusaoi(Japan)
Hiroaki Ogata (Japan)

Lists of organizations

the Joint 14th ISFA World Congress and 4th E-ISFA European Congress

Mon, 12 Jun 2023 10:04:56 +0900

Congress Website

ISFA 2023 Final Program

Detail Program - ISFA 2023

ISFA 2025 Bangkok ---SAVE THE DATE！ July 17-19, 2025 ---

Fri, 9 Jun 2023 13:06:05 +0900

ISFA 2025 Bangkok

ISFA2025　Congress　Website

ISFA2025 Poster PDF

Congress Venue

THE BERKELEY HOTEL PRATUNAM

559 Ratchaprarop Rd, Makkasan, Ratchathewi, Bangkok 10400

https://maps.app.goo.gl/1NLrrTphJV2KapdJ9

https://berkeleypratunam.com/hotel-contact/#hotel

ISFA 2023 Joint Apheresis Congress | Deadline approaching for abstract submission and early bird fee

Wed, 22 Mar 2023 08:17:10 +0900

Deadline abstract submission & early bird approaching

Just a quick reminder that the deadline for abstract submission and early bird registration for the World Apheresis Congress, the Joint 14^th ISFA World Congress and 4^th E-ISFA European Congress is approaching and will be on Friday, March 31!

The scientific program is dedicated to the following current research areas:

Apheresis around the world
Lipid disorders and cardiovascular diseases
Autoimmune diseases
Apheresis in critical care medicine
COVID-19
Registries
Future perspectives of apheresis therapy
Paediatric apheresis
New guidelines and developments

The detailed program available on the congress website.

We warmly welcome all novel contributions for poster and oral presentations. To submit your abstract, follow the link on the congress website or click here.

Be part of the most important International and European Apheresis congress in 2023 and register online now. Deadline for Registration at the Early Bird Fee is March 31, 2023.

Let’s meet in early summer in Berlin!

With best wishes

ISFA + E-ISFA 2023 Congress Organization
c/o K.I.T. Group GmbH Dresden
Bautzner Str. 117–119
01099 Dresden, Germany

Phone: + 49 351 65573135
info@isfa2023.com | www.isfa2023.com

#isfa2023 #apheresis

__________________________________________

Preliminary Program ISFA 2023

Tue, 14 Mar 2023 10:26:37 +0900

Scientific program online

Dear Apheresis Community,

We are pleased to inform you that the preliminary program for the Joint 14^th ISFA World Congress and 4^th E-ISFA European Congress is now available on the congress website.

The ISFA – E-ISFA Organizing and Scientific Committees focused the program on apheresis therapy and COVID-19, lipid disorders as well as apheresis around the world. Furthermore, we offer sessions on apheresis in transplantation and critical care, autoimmune diseases, pediatric apheresis and future perspectives of apheresis therapy. For detailed information please visit the congress website.

We would also like to inform you that the deadline for abstract submission has been extended to March 31. We cordially invite you to join us on this occasion and warmly welcome all novel contributions for poster and oral presentations. To submit your abstract, follow the link on the congress website or click here.

Be part of the most important International and European Apheresis congress in 2023 and register online now. Deadline for Registration at the Early Bird Fee is March 31, 2023.

Further up-to-date information on the congress is provided continuously on the congress homepage: https://www.isfa2023.com/

On behalf of the whole Organizing Committee, we thank you very much in advance for your contribution and support.

We would be very pleased to welcome you in June 2023 in Berlin at the joint ISFA and E-ISFA congress and are happy to answer any questions in the meantime.

Many thanks and best regards

ISFA + E-ISFA 2023 Congress Organization
c/o K.I.T. Group GmbH Dresden
Bautzner Str. 117–119
01099 Dresden, Germany
info@isfa2023.com | www.isfa2023.com

#isfa2023 #apheresis

Preview_ISFA23_Flyer_8S

Call For Abstract / Deadline Extended

Thu, 16 Feb 2023 10:14:09 +0900

Call For Abstract　

Start: December 01, 2022 | Deadline: March 31, February 15, 2023

Dear Apheresis Community,

We are pleased to inform you that the abstract submission and registration for the Joint 14th ISFA World Congress and 4th E-ISFA European Congress is now available on the congress website.

The Joint Congress will take place as an in-person event in Berlin, Germany, from June 1-3, 2023.

The ISFA – E-ISFA Organizing and Scientific Committees cordially invite you to join us on this occasion and warmly welcome all novel contributions for poster and oral presentations.

The congress covers the entire spectrum of research and development in the field of therapeutic apheresis and will also provide a platform to discuss new treatment options arising from the development of innovative drugs and their impact on apheresis treatment in the future. We will also combine parts of this congress with virtual reality workshops bridging the gap between Berlin and the world.

The main topics for abstracts are:

• Development of apheresis technologies

• Apheresis around the world

• Apheresis in critical care

• Apheresis in transplantation

• Hemorheopheresis

• Apheresis therapy and COVID-19 (acute and long term)

• Apheresis therapy in children and during pregnancy

• Apheresis Registries

• Safety and quality of care in extracorporeal therapy

• Psychosocial aspects in patients undergoing extracorporeal therapy

• Vascular access

• Design of clinical apheresis trials

• Autoimmunity

• Cardiometabolic risk factors

• Pathomechanisms in apheresis related diseases

• Novel drug developments in apheresis related diseases

To submit your abstract, follow the link on the congress website or click here. Deadline for abstract submission is Wednesday, February 15, 2023, 23:59 CET.

Be part of the Joint Congress of the most important International and European Apheresis meetings and register online now. Deadline for Registration at the Early Bird Fee is March 31, 2023.

Further up-to-date information on the congress is provided continuously on the congress homepage: https://www.isfa2023.com/

On behalf of the whole Organizing Committee, we thank you very much in advance for your contribution and support.

We would be very pleased to welcome you in June 2023 in Berlin at the joint ISFA and E-ISFA congress and are happy to answer any questions in the meantime.

Many thanks and best regards,

Anja Binning

Project manager

ISFA + E-ISFA 2023 Congress Organization

c/o K.I.T. Group GmbH Dresden

Bautzner Str. 117–119

01099 Dresden, Germany

info@isfa2023.com | www.isfa2023.com

#isfa2023 #apheresis

Print On Demand for 2023 TAD

Wed, 1 Feb 2023 09:24:13 +0900

Wiley provides ISFA Member with Member Direct Print on Demand Ordering Procedures.
ISFA members who has finished the annual due can purchase POD on Member Special Discount Price.

Password for POD: ******* (Password is revealed on "Member Only Items") Please do not share this PW to any non-paid individuals.

For assistance or questions, please contact Sheridan Print on Demand Customer Service at: sheridan.pod@sheridan.com
Navigate to: https://ondemand.sheridan.com/pages/wiley-home.
Use the search box or scroll down the alphabetical list to find the title you would like to purchase.

Member Direct POD - Ordering Instructions

International Society For Apheresis

Linked in

Save the Date / ISFA 2027 San Diego

ISFA SMS Committee

ISFA SMS Committee Members

America

Europe

Pan-Pacific

ISFA SMS Policy

Social Media Policy

Purpose

Rules & Guidelines

ISFA 2025 Banglkok

ISFA 2025

ORGANIZATION 14TH TERM (2025－2027)

Current Presidential greeting

The Officers and The Board of Trustees of 14th Term (2025-2027)

President

President-elect

Immediate Past-President

Congress President

Vice President

Secretary Treasurer

Editor-in Chief

Regional Officers

The Board of Trustees

America

Europe

Pan-Pacific

New Corporate Member / Terumo BCT

Terumo Blood and Cell Technologies

Impact Factor for 2024 is 1.2

Privacy Policy

Past Conferences

Impact Factor for 2022 is 1.900

ORGANIZATION 13TH TERM (2023－2025)

Current president greeting

The Officers and The Board of Trustees of 13th Term (2023-2025)

President

President-elect

Immediate Past-President

Congress President

Vice President

Secretary Treasurer

Editor-in Chief

Regional Officers

The Board of Trustees

America

Europe

Pan-Pacific

the Joint 14th ISFA World Congress and 4th E-ISFA European Congress

ISFA 2025 Bangkok ---SAVE THE DATE！ July 17-19, 2025 ---

ISFA 2023 Joint Apheresis Congress | Deadline approaching for abstract submission and early bird fee

Preliminary Program ISFA 2023

Call For Abstract / Deadline Extended

Print On Demand for 2023 TAD

ISFA SMS Committee　Members

The Officers and The Board of Trustees of 14th Term　(2025-2027)

The Officers and The Board of Trustees of 13th Term　(2023-2025)